The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.
Wang A, Singh K, Ibrahim W, King B, Damsky W. The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature. The Yale Journal Of Biology And Medicine 2020, 93: 187-195. PMID: 32226347, PMCID: PMC7087061.Peer-Reviewed Original ResearchConceptsInflammatory disordersMacrophage activationJAK inhibitorsCertain inflammatory disordersTreatment of sarcoidosisFormation of granulomasCrohn's diseaseClinical evidenceNecrobiosis lipoidicaInflammatory cytokinesDependent cytokinesGranuloma annulareGranuloma formationInterferon gammaJAK inhibitionJAK-STAT pathwaySarcoidosisDisordersCytokinesInhibitorsConstitutive activationDiseaseActivationDramatic improvementGranulomasTreatment of Multiorgan Sarcoidosis With Tofacitinib
Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology 2020, 2: 106-109. PMID: 31916703, PMCID: PMC7011417, DOI: 10.1002/acr2.11112.Peer-Reviewed Original ResearchMultiorgan sarcoidosisTumor necrosis factor α blockadeNecrosis factor α blockadeCutaneous sarcoidosis lesionsEfficacy of tofacitinibIdiopathic inflammatory disorderJanus kinase inhibitorRecalcitrant sarcoidosisΑ-blockadeClinical remissionSarcoidosis lesionsGranulomatous inflammationInflammatory disordersAvid lesionsLesional tissueSarcoidosisJanus kinase-signal transducerSingle patientJAK inhibitorsJAK inhibitionKinase-signal transducerTofacitinibKinase inhibitorsActivator of transcriptionInternal organs